[Gly22]-beta-Amyloid (1-40), Arctic Mutation – 0.5 mg

Overview

The [Gly22]-beta-Amyloid (1-40), Arctic Mutation is an essential peptide for researchers investigating the mechanisms of early onset familial Alzheimer’s disease. This specific mutation, where Glu 22 is replaced by Gly, is known to significantly enhance the aggregation of beta-Amyloid (Aβ) proteins, leading to the formation of Aβ protofibrils. Understanding these processes is crucial for developing potential therapeutic strategies against Alzheimer’s.

Key Features

• High purity peptide for accurate research results
• Specifically designed for studies on familial Alzheimer’s disease
• Facilitates the examination of beta-Amyloid aggregation
• Supports a range of experimental applications, including in vitro and in vivo studies

Specifications

FAQ

What applications is the [Gly22]-beta-Amyloid suitable for?

This peptide is ideal for studies focused on Alzheimer’s disease, specifically assessing the aggregation behavior of beta-Amyloid proteins.

How should I store the [Gly22]-beta-Amyloid peptide?

For best results, store the peptide at -20°C, avoiding repeated freeze-thaw cycles to maintain its integrity.

Can this peptide be used for in vivo studies?

Yes, the [Gly22]-beta-Amyloid can be utilized in both in vitro and in vivo studies to explore the mechanisms of Alzheimer’s disease.

Explore more of our offerings, including our PKG Substrate and the innovative Autocamtide-2. By integrating these products with the [Gly22]-beta-Amyloid, you can enhance your research scope and outcomes. Purchasing from AnaSpec ensures you receive high-quality reagents that meet your experimental needs.

Related Products

• CREBtide [KRREILSRRPSYR], 5-FAM labeled

Browse more in Peptides.